Clinical Laserthermia Systems (CLS) develops and sells TRANBERG Thermal Therapy-products for thermal ablation in urology, oncology and neurosurgery.
The company is focusing on commercialization in the US and Europe, and is now expanding into the Asia-Pacific region. CLS has received market approval for its entire portfolio of TRANBERG Thermal Therapy products by Health Sciences Authority (HSA) in Singapore.
Market approval in Singapore
The HSA has approved the use of the TRANBERG products for thermal ablation of pathological soft tissue for tumor control, symptom relief, and to restore physiological functions in patients with prostate cancer or tumors of the liver.
With market approval in place, CLS can begin the commercialization process in Singapore, which is being carried out by the joint venture company CLS Asia Pacific PTE. LTD, headquartered in the Republic of Singapore.
Broader commercialization in sight
The approval also opens the door to broader commercialization in the Asia-Pacific region. According to the company's latest report, the approval could potentially accelerate approval processes in other markets within the region.
CLS CEO Dan J. Mogren commented on the good news in a press release:
“This is a long-awaited breakthrough that we have been working hard for for a long time. The Asia-Pacific region is a populous region with growing medical needs, where our TRANBERG portfolio for minimally invasive focal laser ablation can be of great value to patients and healthcare providers. Through CLS Asia Pacific, we have already established clinical relationships in the region and now intend to deepen these and begin commercialization of our product portfolio.”
By expanding into the Asia-Pacific region, CLS is diversifying its geographic presence. The company expects the region to be a key contributor to achieving its revenue target of SEK 100 million by 2025.